Introduction:Basic information about CAS 518-17-2|Evodiamine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Evodiamine |
|---|
| CAS Number | 518-17-2 | Molecular Weight | 303.358 |
|---|
| Density | 1.4±0.1 g/cm3 | Boiling Point | 575.1±50.0 °C at 760 mmHg |
|---|
| Molecular Formula | C19H17N3O | Melting Point | 263 - 265ºC |
|---|
| MSDS | USA | Flash Point | 301.6±30.1 °C |
|---|
Names
| Name | Evodiamine |
|---|
| Synonym | More Synonyms |
|---|
Evodiamine BiologicalActivity
| Description | Evodiamine is an alkaloid isolated from the fruit of Evodia rutaecarpa Bentham with diverse biological activities including anti-inflammatory, anti-obesity, and antitumor. |
|---|
| Related Catalog | Signaling Pathways >>Others >>OthersResearch Areas >>CancerNatural Products >>Alkaloid |
|---|
| In Vitro | Evodiamine shows cytotoxicity against a variety of human cancer cell-lines by inducing apoptosis. Moreover, it is a naturally multi-targeting antitumor molecule, which exerts the antitumor activity by various molecular mechanism such as caspase-dependent and -independent pathways, sphingomyelin pathway, calcium/JNK signaling, 31 PI3K/Akt/caspase and Fas-L/NF-κB signaling pathways32[1]. |
|---|
| In Vivo | Evodiamine inhibits the metabolism of dapoxetine. Compared to the control group, the pharmacokinetic parameter of t1/2, AUC(0-∞) and Tmax of dapoxetine in evodiamine group is significantly increased by 63.3%, 44.8% and 50.4%, respectively. Moreover, evodiamine has significantly decreased the pharmacokinetic parameter of t1/2 and AUC(0-∞) of desmethyl dapoxetine[2]. Evodiamine suppresses tumor growth in a subcutaneous H22 xenograft model. Evodiamine attenuates VEGF-induced angiogenesis in vivo[3]. |
|---|
| Cell Assay | Evodiamine is dissolved in DMSO and diluted with appropriate medium before use. The evodiamine-inspired new scaffolds are assayed for growth inhibitory activities toward human cancer cell-lines A549 (lung cancer), MDA-MB-435 (breast cancer) and HCT116 (colon cancer) using the MTT assay. Evodiamine and camptithecin are used as reference drugs[1]. |
|---|
| Animal Admin | Rats: Twelve healthy male Sprague-Dawley rats are randomly divided into 2 groups: the control group (received oral 10 mg/kg dapoxetine alone) and the combination group (10 mg/kg dapoxetine orally co-administered with 100 mg/kg evodiamine). The plasma concentration of dapoxetine and desmethyl dapoxetine are estimated by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and different pharmacokinetic parameters are calculated[2]. Mice: A nude mouse xenograft model is established by using 4–6-week-old male BALB/c nude mice. Mice are dosed daily with 20 mg/kg (10 mL/kg) of evodiamine intragastrically, six mice are dosed intraperitoneally with 10 mg/kg of 5-flurouracil (5-FU) twice a week, and six mice are not treated. The tumor volumes are determined by measuring two dimensions, with tumor volume=length×width×width/2. After 2 or 3 weeks of treatment, mice are sacrificed by cervical dislocation under anesthesia with ether, and the tumor tissues are collected[3]. |
|---|
| References | [1]. Wang S, et al. Scaffold Diversity Inspired by the Natural Product Evodiamine: Discovery of Highly Potent and Multitargeting Antitumor Agents. J Med Chem. 2015 Aug 27;58(16):6678-96. [2]. Li RF,et al. Effects of Evodiamine on the Pharmacokinetics of Dapoxetine and Its Metabolite Desmethyl Dapoxetine inRats. Pharmacology. 2016;97(1-2):43-7. [3]. Shi L, et al. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis. Tumour Biol. 2016 Sep;37(9):12791-12803. |
|---|
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|
| Boiling Point | 575.1±50.0 °C at 760 mmHg |
|---|
| Melting Point | 263 - 265ºC |
|---|
| Molecular Formula | C19H17N3O |
|---|
| Molecular Weight | 303.358 |
|---|
| Flash Point | 301.6±30.1 °C |
|---|
| Exact Mass | 303.137177 |
|---|
| PSA | 39.34000 |
|---|
| LogP | 1.64 |
|---|
| Vapour Pressure | 0.0±1.6 mmHg at 25°C |
|---|
| Index of Refraction | 1.764 |
|---|
| InChIKey | TXDUTHBFYKGSAH-SFHVURJKSA-N |
|---|
| SMILES | CN1c2ccccc2C(=O)N2CCc3c([nH]c4ccccc34)C21 |
|---|
| Storage condition | 2-8°C |
|---|
Safety Information
| Hazard Codes | T |
|---|
| Risk Phrases | R25 |
|---|
| Safety Phrases | S45 |
|---|
| RIDADR | UN 2811 6.1/PG 3 |
|---|
| Hazard Class | 6.1 |
|---|
| HS Code | 2933990090 |
|---|
Customs
| HS Code | 2933990090 |
|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
|---|
Synonyms
| EVODIAMINE PLANT EXTRACT |
| Indolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (13bS)- |
| Evodia rutaecarpa E.P. |
| Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (13bS)- |
| Indol(2',3':3,4)pyrido(2,1-b)quinazolin-5(7H)-one, 8,13,13b,14-tetrahydro-14-methyl-, (S)- |
| d-Evodiamine |
| (13bS)-14-Methyl-8,13,13b,14-tetrahydroindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one |
| MFCD06407824 |